Market capitalization | $136.12m |
Enterprise Value | $131.11m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
EV/Sales (TTM) EV/Sales | 3.74 |
P/S ratio (TTM) P/S ratio | 3.88 |
P/B ratio (TTM) P/B ratio | 8.33 |
Revenue growth (TTM) Revenue growth | 19.65% |
Revenue (TTM) Revenue | $35.08m |
As a Free StocksGuide user, you can view scores for all 6,789 stocks worldwide.
5 Analysts have issued a Repro-Med Systems, Inc. forecast:
5 Analysts have issued a Repro-Med Systems, Inc. forecast:
Mar '25 |
+/-
%
|
||
Revenue | 35 35 |
20%
20%
|
|
Gross Profit | 21 21 |
28%
28%
|
|
EBITDA | -4.86 -4.86 |
41%
41%
|
EBIT (Operating Income) EBIT | -5.73 -5.73 |
38%
38%
|
Net Profit | -5.30 -5.30 |
60%
60%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Repro-Med Systems, Inc. engages in the design, manufacture, and market of proprietary medical devices. Its product portfolio includes FREEDOM60, FreedomEdge syringe drivers, Precision Flow Rate Tubing, and HIgH-Flo Subcutaneous Safety Needle Sets. The company was founded by Andrew I. Sealfon and Adrian W. Zorgniotti on March 24, 1980 and is headquartered in Chester, NY.
Head office | United States |
CEO | Linda Tharby |
Employees | 80 |
Founded | 1980 |
Website | www.korumedical.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.